• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIGHT SCIENCES, INC. OMNI GLAUCOMA TREATMENT SYSTEM; VISCOELASTIC INJECTOR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIGHT SCIENCES, INC. OMNI GLAUCOMA TREATMENT SYSTEM; VISCOELASTIC INJECTOR Back to Search Results
Model Number 1-101
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Corneal Edema (1791); Hypopyon (1913); Inflammation (1932); Intraocular Pressure Increased (1937); Visual Impairment (2138)
Event Date 01/23/2018
Event Type  Injury  
Manufacturer Narrative
The device was discarded by the facility and is not available for evaluation.Device did not provide lot number of device used.Mfr reference #: (b)(4).
 
Event Description
On (b)(6) 2018, the surgeon performed vasodilation and trabeculotomy with the omni device on the patient's right eye.The surgeon then performed phacoemulsification and insertion of an intraocular lens.The surgeon administered intracameral cefuroxime 1mg/0.1ml at the end of the procedure.There were no intraoperative complications.On (b)(6) 2018, the patient was diagnosed with mild-moderate corneal edema, iop elevation (28mhg), anterior chamber inflammation, hypopyon, and mild pain which was diagnosed as toxic anterior segment syndrome (tass).Patient's best corrected visual acuity had decreased from 0.4 pre-operatively to 0.2 at the onset of the event.No cultures were obtained.The patient was treated with topical cycloplegic drops (10 mg/ml of cyclopentolate hydrocloride) and azara (10 mg/ml plus 5 mg/ml of brinzolamide, timolol maleate).The event was resolved by (b)(6) 2018.The patient's iop has improved to 14 mmhg and the best corrected visual acuity has improved to 0.7.No other cases of tass or endophthalmitis were reported at the facility around the time of the event.The surgeon did not believe the omni device was the cause or a contributing factor in this event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OMNI GLAUCOMA TREATMENT SYSTEM
Type of Device
VISCOELASTIC INJECTOR
Manufacturer (Section D)
SIGHT SCIENCES, INC.
3000 sand hill rd., 3-105
menlo park CA 94025
Manufacturer (Section G)
SIGHT SCIENCES, INC.
3000 sand hill rd., 3-105
menlo park CA 94025
Manufacturer Contact
anne-marie ripley
3000 sand hill rd., 3-105
menlo park, CA 94025
6616458546
MDR Report Key7747644
MDR Text Key115955747
Report Number3010363671-2018-00001
Device Sequence Number1
Product Code MRH
Combination Product (y/n)N
Reporter Country CodeSP
PMA/PMN Number
K173332
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Type of Report Initial
Report Date 08/03/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/03/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number1-101
Device Catalogue Number1-101
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/24/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age67 YR
-
-